Zhuhai Rundu Pharmaceutical (SHE:002923) obtained Chinese marketing approval for the isosorbide dinitrate active pharmaceutical ingredient for coronary heart disease, according to a Friday filing with the Shenzhen bourse.
The drug is indicated for angina pectoris or chest pain, especially after a myocardial infarction or a heart attack, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments